Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TITAN: Phase I Open-label Study of AZD5492 in Autoimmune Diseases
jRCT2071250048Phase 1Recruiting
- Sponsor
- AstraZeneca
- Start
- Aug 2025
- Modality
- Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 1, open-label trial of AZD5492 in systemic lupus erythematosus (SLE), Autoimmune Myopathies, polymyositis (PM) and 2 more (2 arms), sponsored by AstraZeneca. Primary endpoint: Safety and tolerability of AZD5492. Started Aug 2025; status: recruiting.
02
Drugs
AZD5492
03
Conditions
systemic lupus erythematosus (SLE)Autoimmune Myopathiespolymyositis (PM)dermatomyositis (DM)rheumatoid arthritis (RA)
Beyond the preview
Go deeper on jRCT2071250048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071250048.